Burton, Anya http://orcid.org/0000-0002-4416-0538
Wilburn, Jennifer
Driver, Robert J.
Wallace, David
McPhail, Sean
Cross, Tim J. S. http://orcid.org/0000-0003-0625-8726
Rowe, Ian A. http://orcid.org/0000-0003-1288-0749
Marshall, Aileen
Article History
Received: 22 June 2023
Revised: 22 February 2024
Accepted: 26 February 2024
First Online: 18 March 2024
Competing interests
: All of the authors completed the ICMJE uniform disclosure form; AB declares this work was supported by BTG International Ltd. AM is the chair of HCC UK. TJSC is President elect of the British Association for the Study of the Liver, has shares in AstraZeneca, has given talks for Roche, AstraZeneca, received financial support for educational events from Boston Scientific and Sirtex, works for Roche pharmaceuticals on HCC patient pathways and use of surveillance for HCC, and Roche paid for TJSC’ 2022 attendance at ASCO. IAR reports personal fees from Roche, as well as personal fees from Boehringer Ingelheim outside the submitted work. The other authors declare no competing interests.
: This study was conducted under a special legal instruction to collect patient data without needing informed consent, as part of NHS England. This instruction is granted under section 254 of the Health and Social Care Act 2012.